Which has preferable valuation & earnings, PCVX or BIIB?

Biogen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$8.06 N/A Biogen $9.89B 3.79 $1.29B $2.34 108.29

Is PCVX or BIIB more profitable?

Biogen has a net margin of 3.37% compared to Vaxcyte's net margin of 0.00%. Biogen's return on equity of 9.38% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -42.04% -36.82% Biogen 3.37% 9.38% 5.69%

Does the media refer more to PCVX or BIIB?

In the previous week, Biogen had 19 more articles in the media than Vaxcyte. MarketBeat recorded 26 mentions for Biogen and 7 mentions for Vaxcyte. Biogen's average media sentiment score of 1.37 beat Vaxcyte's score of 0.94 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 20 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher earnings & valuation, GMAB or PCVX?

Genmab A/S has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $4.30B 7.83 $963M $1.17 46.04 Vaxcyte N/A N/A -$766.63M -$8.06 N/A

Is GMAB or PCVX more profitable?

Genmab A/S has a net margin of 16.97% compared to Vaxcyte's net margin of 0.00%. Genmab A/S's return on equity of 13.67% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 16.97% 13.67% 6.42% Vaxcyte N/A -42.04% -36.82%

Does the media favor GMAB or PCVX?

In the previous week, Genmab A/S had 16 more articles in the media than Vaxcyte. MarketBeat recorded 23 mentions for Genmab A/S and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat Genmab A/S's score of 0.21 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PCVX or ALNY?

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Vaxcyte. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat Alnylam Pharmaceuticals' score of 0.44 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Is PCVX or ROIV more profitable?

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -838.21%. Roivant Sciences' return on equity of -22.03% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -42.04% -36.82% Roivant Sciences -838.21% -22.03% -20.55%

Does the media favor PCVX or ROIV?

In the previous week, Roivant Sciences had 20 more articles in the media than Vaxcyte. MarketBeat recorded 27 mentions for Roivant Sciences and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat Roivant Sciences' score of 0.59 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or PCVX?

In the previous week, United Therapeutics had 37 more articles in the media than Vaxcyte. MarketBeat recorded 44 mentions for United Therapeutics and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat United Therapeutics' score of 0.67 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 20 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vaxcyte (PCVX) Competitors

$68.62 +2.26 (+3.41%)

Closing price 11/11/2026 04:00 PM Eastern

Extended Trading

$68.01 -0.61 (-0.89%)

As of 06:16 AM Eastern

Compare

PCVX vs. BIIB, GMAB, ALNY, ROIV, and UTHR

Should you buy Vaxcyte stock or one of its competitors? Vaxcyte's main competitors and comparable companies include Biogen (BIIB), Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), and United Therapeutics (UTHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vaxcyte compare to Biogen?

Vaxcyte (NASDAQ:PCVX) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biogen had 19 more articles in the media than Vaxcyte. MarketBeat recorded 26 mentions for Biogen and 7 mentions for Vaxcyte. Biogen's average media sentiment score of 1.37 beat Vaxcyte's score of 0.94 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	20 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Vaxcyte presently has a consensus target price of $110.50, suggesting a potential upside of 61.03%. Biogen has a consensus target price of $254.41, suggesting a potential upside of 0.40%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Biogen	1 Sell rating(s)	10 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.67

Vaxcyte has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Biogen has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Biogen has a net margin of 3.37% compared to Vaxcyte's net margin of 0.00%. Biogen's return on equity of 9.38% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-42.04%	-36.82%
Biogen	3.37%	9.38%	5.69%

Biogen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$8.06	N/A
Biogen	$9.89B	3.79	$1.29B	$2.34	108.29

Summary

Biogen beats Vaxcyte on 11 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Vaxcyte (NASDAQ:PCVX) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Genmab A/S has a net margin of 16.97% compared to Vaxcyte's net margin of 0.00%. Genmab A/S's return on equity of 13.67% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	16.97%	13.67%	6.42%
Vaxcyte	N/A	-42.04%	-36.82%

Genmab A/S has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$4.30B	7.83	$963M	$1.17	46.04
Vaxcyte	N/A	N/A	-$766.63M	-$8.06	N/A

Genmab A/S has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, Genmab A/S had 16 more articles in the media than Vaxcyte. MarketBeat recorded 23 mentions for Genmab A/S and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat Genmab A/S's score of 0.21 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S presently has a consensus target price of $53.61, suggesting a potential downside of 0.48%. Vaxcyte has a consensus target price of $110.50, suggesting a potential upside of 61.03%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.00
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Genmab A/S beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Alnylam Pharmaceuticals?

Vaxcyte (NASDAQ:PCVX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vaxcyte currently has a consensus price target of $110.50, suggesting a potential upside of 61.03%. Alnylam Pharmaceuticals has a consensus price target of $305.86, suggesting a potential upside of 91.34%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alnylam Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.65

Alnylam Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$8.06	N/A
Alnylam Pharmaceuticals	$3.71B	5.76	$313.75M	$19.26	8.30

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Vaxcyte. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat Alnylam Pharmaceuticals' score of 0.44 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Vaxcyte's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-42.04%	-36.82%
Alnylam Pharmaceuticals	52.85%	155.33%	44.81%

Vaxcyte has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Roivant Sciences?

Vaxcyte (NASDAQ:PCVX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Roivant Sciences has higher revenue and earnings than Vaxcyte. Roivant Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$8.06	N/A
Roivant Sciences	$8.26M	3,659.70	-$299.77M	-$0.53	N/A

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Roivant Sciences had 20 more articles in the media than Vaxcyte. MarketBeat recorded 27 mentions for Roivant Sciences and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat Roivant Sciences' score of 0.59 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte presently has a consensus price target of $110.50, indicating a potential upside of 61.03%. Roivant Sciences has a consensus price target of $46.64, indicating a potential upside of 11.44%. Given Vaxcyte's higher possible upside, equities research analysts clearly believe Vaxcyte is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Roivant Sciences	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Vaxcyte has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -838.21%. Roivant Sciences' return on equity of -22.03% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-42.04%	-36.82%
Roivant Sciences	-838.21%	-22.03%	-20.55%

Summary

Roivant Sciences beats Vaxcyte on 10 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Vaxcyte (NASDAQ:PCVX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

United Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.97	$1.33B	$26.50	22.48
Vaxcyte	N/A	N/A	-$766.63M	-$8.06	N/A

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, United Therapeutics had 37 more articles in the media than Vaxcyte. MarketBeat recorded 44 mentions for United Therapeutics and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.94 beat United Therapeutics' score of 0.67 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	20 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 38.61% compared to Vaxcyte's net margin of 0.00%. United Therapeutics' return on equity of 19.18% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	38.61%	19.18%	17.07%
Vaxcyte	N/A	-42.04%	-36.82%

United Therapeutics presently has a consensus price target of $676.40, indicating a potential upside of 13.55%. Vaxcyte has a consensus price target of $110.50, indicating a potential upside of 61.03%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Summary

United Therapeutics beats Vaxcyte on 11 of the 15 factors compared between the two stocks.

Get Vaxcyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCVX vs. The Competition

Export

Metric	Vaxcyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.50B	$4.15B	$7.90B	$12.02B
Dividend Yield	N/A	3.63%	2.45%	4.46%
P/E Ratio	-8.51	26.29	34.12	30.28
Price / Sales	N/A	16.14	8.57	5.64
Price / Cash	N/A	26.63	22.08	22.50
Price / Book	4.36	4.23	4.52	3.80
Net Income	-$766.63M	-$22.78M	$3.50B	$390.04M
7 Day Performance	10.82%	3.88%	2.51%	3.40%
1 Month Performance	-2.87%	-5.15%	-3.24%	-5.35%
1 Year Performance	48.85%	-0.44%	1.00%	-5.92%

Vaxcyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCVX Vaxcyte	3.2312 of 5 stars	$68.62 +3.4%	$110.50 +61.0%	+50.3%	$10.50B	N/A	N/A	507	Positive News
BIIB Biogen	3.0651 of 5 stars	$249.01 -1.8%	$252.34 +1.3%	+58.8%	$36.06B	$9.89B	20.72	7,500	Positive News Analyst Forecast
GMAB Genmab A/S	2.2848 of 5 stars	$54.92 -3.8%	$53.61 -2.4%	+77.7%	$35.61B	$4.13B	43.24	3,029	Trending News Earnings Report Analyst Upgrade Short Interest Increase Analyst Revision Gap Down
ALNY Alnylam Pharmaceuticals	4.8445 of 5 stars	$158.00 -4.2%	$305.86 +93.6%	-64.6%	$31.10B	$3.71B	8.20	2,770	High Trading Volume
ROIV Roivant Sciences	1.7638 of 5 stars	$35.89 -2.8%	$46.55 +29.7%	+100.2%	$26.81B	$8.26M	N/A	721	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCVX) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Competitors

PCVX vs. BIIB, GMAB, ALNY, ROIV, and UTHR

How does Vaxcyte compare to Biogen?

Summary

How does Vaxcyte compare to Genmab A/S?

Summary

How does Vaxcyte compare to Alnylam Pharmaceuticals?

Summary

How does Vaxcyte compare to Roivant Sciences?

Summary

How does Vaxcyte compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX vs. The Competition

Vaxcyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaxcyte (PCVX) Competitors

PCVX vs. BIIB, GMAB, ALNY, ROIV, and UTHR

How does Vaxcyte compare to Biogen?

Do institutionals and insiders believe in PCVX or BIIB?

Does the media refer more to PCVX or BIIB?

Do analysts prefer PCVX or BIIB?

Which has more volatility & risk, PCVX or BIIB?

Is PCVX or BIIB more profitable?

Which has preferable valuation & earnings, PCVX or BIIB?

Summary

How does Vaxcyte compare to Genmab A/S?

Is GMAB or PCVX more profitable?

Which has higher earnings & valuation, GMAB or PCVX?

Which has more volatility and risk, GMAB or PCVX?

Does the media favor GMAB or PCVX?

Do institutionals and insiders hold more shares of GMAB or PCVX?

Do analysts recommend GMAB or PCVX?

Summary

How does Vaxcyte compare to Alnylam Pharmaceuticals?

Do institutionals & insiders hold more shares of PCVX or ALNY?

Do analysts prefer PCVX or ALNY?

Which has preferable valuation & earnings, PCVX or ALNY?

Does the media favor PCVX or ALNY?

Is PCVX or ALNY more profitable?

Which has more risk & volatility, PCVX or ALNY?

Summary

How does Vaxcyte compare to Roivant Sciences?

Which has stronger earnings & valuation, PCVX or ROIV?

Do insiders & institutionals believe in PCVX or ROIV?

Does the media favor PCVX or ROIV?

Do analysts prefer PCVX or ROIV?

Which has more volatility & risk, PCVX or ROIV?

Is PCVX or ROIV more profitable?

Summary

How does Vaxcyte compare to United Therapeutics?

Which has stronger valuation and earnings, UTHR or PCVX?

Do insiders and institutionals have more ownership in UTHR or PCVX?

Does the media prefer UTHR or PCVX?

Is UTHR or PCVX more profitable?

Do analysts prefer UTHR or PCVX?

Which has more volatility and risk, UTHR or PCVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX vs. The Competition

Vaxcyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools